Literature DB >> 17365509

Evidence that calmodulin binding to the dopamine D2 receptor enhances receptor signaling.

Yong Liu1, David C Buck, Tara A Macey, Hongxiang Lan, Kim A Neve.   

Abstract

The Ca2+ sensor calmodulin (CaM) regulates numerous proteins involved in G protein-coupled receptor (GPCR) signaling. CaM binds directly to some GPCRs, including the dopamine D2 receptor. We confirmed that the third intracellular loop of the D2 receptor is a direct contact point for CaM binding using coimmunoprecipitation and a polyHis pull-down assay, and we determined that the D2-like receptor agonist 7-OH-DPAT increased the colocalization of the D2 receptor and endogenous CaM in both 293 cells and in primary neostriatal cultures. The N-terminal three or four residues of D2-IC3 were required for the binding of CaM; mutation of three of these residues in the full-length receptor (I210C/K211C/I212C) decreased the coprecipitation of the D2 receptor and CaM and also significantly decreased D2 receptor signaling, without altering the coupling of the receptor to G proteins. Taken together, these findings suggest that binding of CaM to the dopamine D2 receptor enhances D2 receptor signaling.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17365509     DOI: 10.1080/10799890601094152

Source DB:  PubMed          Journal:  J Recept Signal Transduct Res        ISSN: 1079-9893            Impact factor:   2.092


  11 in total

Review 1.  An update on adenosine A2A-dopamine D2 receptor interactions: implications for the function of G protein-coupled receptors.

Authors:  S Ferré; C Quiroz; A S Woods; R Cunha; P Popoli; F Ciruela; C Lluis; R Franco; K Azdad; S N Schiffmann
Journal:  Curr Pharm Des       Date:  2008       Impact factor: 3.116

Review 2.  Dopamine D2 autoreceptor interactome: Targeting the receptor complex as a strategy for treatment of substance use disorder.

Authors:  Rong Chen; Mark J Ferris; Shiyu Wang
Journal:  Pharmacol Ther       Date:  2020-05-27       Impact factor: 12.310

3.  Interactions between calmodulin, adenosine A2A, and dopamine D2 receptors.

Authors:  Gemma Navarro; Marisol S Aymerich; Daniel Marcellino; Antoni Cortés; Vicent Casadó; Josefa Mallol; Enric I Canela; Luigi Agnati; Amina S Woods; Kjell Fuxe; Carmen Lluís; Jose Luis Lanciego; Sergi Ferré; Rafael Franco
Journal:  J Biol Chem       Date:  2009-07-24       Impact factor: 5.157

4.  A dopamine D2 receptor mutant capable of G protein-mediated signaling but deficient in arrestin binding.

Authors:  Hongxiang Lan; Yong Liu; Michal I Bell; Vsevolod V Gurevich; Kim A Neve
Journal:  Mol Pharmacol       Date:  2008-09-22       Impact factor: 4.436

5.  Allosteric effects of the antipsychotic drug trifluoperazine on the energetics of calcium binding by calmodulin.

Authors:  Michael D Feldkamp; Susan E O'Donnell; Liping Yu; Madeline A Shea
Journal:  Proteins       Date:  2010-08-01

Review 6.  Fine-tuning of GPCR activity by receptor-interacting proteins.

Authors:  Stefanie L Ritter; Randy A Hall
Journal:  Nat Rev Mol Cell Biol       Date:  2009-12       Impact factor: 94.444

7.  Novel interaction of the dopamine D2 receptor and the Ca2+ binding protein S100B: role in D2 receptor function.

Authors:  Yong Liu; David C Buck; Kim A Neve
Journal:  Mol Pharmacol       Date:  2008-04-29       Impact factor: 4.436

8.  How calmodulin interacts with the adenosine A(2A) and the dopamine D(2) receptors.

Authors:  Amina S Woods; Daniel Marcellino; Shelley N Jackson; Rafael Franco; Sergi Ferré; Luigi F Agnati; Kjell Fuxe
Journal:  J Proteome Res       Date:  2008-07-01       Impact factor: 4.466

9.  S100 calcium binding proteins and ion channels.

Authors:  Anton Hermann; Rosario Donato; Thomas M Weiger; Walter J Chazin
Journal:  Front Pharmacol       Date:  2012-04-25       Impact factor: 5.810

10.  Signaling-Biased and Constitutively Active Dopamine D2 Receptor Variant.

Authors:  Dayana Rodriguez-Contreras; Alec F Condon; David C Buck; Naeem Asad; Timothy M Dore; Dineke S Verbeek; Marina A J Tijssen; Ujwal Shinde; John T Williams; Kim A Neve
Journal:  ACS Chem Neurosci       Date:  2021-05-11       Impact factor: 5.780

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.